Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07038343). This is a study registration, not published results. Lead sponsor: Avenzo Therapeutics, Inc.. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 480 participants (ESTIMATED). Conditions: Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers. Interventions: DRUG: AVZO-1418; DRUG: Combination Agent 1; DRUG: Combination Agent 2. Primary outcome measures: Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1) , Approximately 2 years; Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1) , Approximately 16 months; Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1) , From baseline until end of study treatment or study completion (approximately 2 years); Objective Response Rate (ORR) (Phase 2) , From baseline through disease progression or study completion (approximately 2 years). Brief summary: This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.